Aarkstore -Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)-Pipeline Insights, 2014

1
Familial Hypercholesterolemia (Type II
Hyperlipoproteinemia)-Pipeline Insights, 2014
Category Pharmaceuticals Healthcare

• Browse Complete Report -
• http//www.aarkstore.com/healthcare/77056/-familia
  l-hypercholesterolemia-type-ii-hyperlipoproteinemi
  a-pipeline-insights-2014

2
Summary

• DelveInsights, Familial Hypercholesterolemia
  (Type II Hyperlipoproteinemia)-Pipeline Insights,
  2014, report provides comprehensive insights
  about pipeline drugs across this indication. A
  key objective of the report is to establish the
  understanding for all the pipeline drugs that
  fall under Familial Hypercholesterolemia (Type II
  Hyperlipoproteinemia). This report provides
  information on the therapeutic development based
  on the Familial Hypercholesterolemia (Type II
  Hyperlipoproteinemia) dealing with all the
  pipeline drugs, comparative analysis at various
  stages covering Filed, Phase III, Phase II, Phase
  I, IND filed, Preclinical, Discovery and unknown
  stages, therapeutics assessment by monotherapy
  and combination products and molecule type drug
  information. The report also covers the companies
  information involved in the therapeutic
  development of the products. It also has
  highlighted the discontinued and dormant products.

3
Summary

• Data Sources
• The report is built using data and information
  sourced from proprietary databases, primary and
  secondary research and in-house analysis by
  DelveInsight team of industry experts.Secondary
  sources information and data has been collected
  from various printable and non-printable sources
  like search engines, News websites, Government
  Websites, Trade Journals, White papers,
  Magazines, Trade associations, Books, Industry
  Portals, Industry Associations and access to
  available databases.Note This report requires
  certain updates. We have all the information
  available but require 3 business days to complete
  the process and ensure it is as up-to-date as
  possible. Certain sections in the report may be
  removed or altered based on the availability and
  relevance of data for the indicated Indication.

4
Summary

• Scope 
• The report provides a snapshot of the global
  therapeutic landscape of Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  )The report provides pipeline products under
  drug profile section which includes product
  description, MOA, licensors collaborators,
  development partner and chemical
  informationCoverage of the Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) pipeline on the basis of target, MOA, route of
  administration, technology involved and molecule
  typeThe report reviews key players involved in
  the therapeutics development for Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) and also provide company profilingThe report
  also gives the information of dormant and
  discontinued pipeline projects Pipeline products
  coverage based on various stages of development
  ranging from preregistration till discovery and
  undisclosed stages Provides pipeline assessment
  by monotherapy and combination therapy products,
  stage of development and molecule type

5
Summary

• Reasons to buyComplete Pipeline intelligence
  and complete understanding over therapeutics
  development for Familial Hypercholesterolemia
  (Type II Hyperlipoproteinemia)Identify the
  relationship between the drugs and use it for
  target finding, drug repurposing, and precision
  medicine.Devise corrective measures for pipeline
  projects by understanding Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) pipeline depth and focus of Indication
  therapeutics Developing strategic initiatives to
  support your drug development activities.Optimize
  your portfolio and keep you in touch with the
  rapidly changing pharmaceutical markets, and make
  the best decisions for your business.

6
Summary

• Develop and design in licensing and out licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and ScopeProvides
  strategically significant competitor information,
  analysis, and insights to formulate effective RD
  development strategies Modify the therapeutic
  portfolio by identifying discontinued projects
  and understanding the factors that drove them
  from pipelineGaining a Full Picture of the
  Competitive Landscape for Evidence based
  Decisions

7
Table of Content

• Familial Hypercholesterolemia (Type II
  Hyperlipoproteinemia) OverviewFamilial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) Pipeline TherapeuticsFamilial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) Therapeutics under Development by
  Companies Familial Hypercholesterolemia (Type II
  Hyperlipoproteinemia) Late Stage Products (Filed
  and Phase III)Comparative Analysis Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) Mid Clinical Stage Products (Phase
  II)Comparative Analysis Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) Early Clinical Stage Products (Phase I and IND
  Filed)Comparative Analysis Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) Discovery and Pre-Clinical Stage
  Products Comparative Analysis Drug Candidate
  Profiles

8
Table of Content

• Familial Hypercholesterolemia (Type II
  Hyperlipoproteinemia) Therapeutics
  Assessment Assessment by Monotherapy
  Products Assessment by Combination
  Products Assessment by Route of
  Administration Assessment by Molecule
  Type Familial Hypercholesterolemia (Type II
  Hyperlipoproteinemia) Discontinued
  Products Familial Hypercholesterolemia (Type II
  Hyperlipoproteinemia) Dormant ProductsCompanies
  Involved in Therapeutics Development for Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) Appendix Methodology Contact Us Disclaimer

9
List of Tables

• Number of Products under Development for Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ), 2014Number of Products under Development by
  Companies Comparative Analysis by Late Clinical
  Stage Products (Filed and Phase III),
  2014Comparative Analysis Mid Clinical Stage
  Products (Phase II), 2014Comparative Analysis
  Early Clinical Stage Products (Phase I and IND
  Filed), 2014Comparative Analysis Discovery and
  Pre-Clinical Stage Products, 2014Drug Candidates
  ProfilesFamilial Hypercholesterolemia (Type II
  Hyperlipoproteinemia) Assessment by Monotherapy
  Products Familial Hypercholesterolemia (Type II
  Hyperlipoproteinemia) Assessment by Combination
  Products Familial Hypercholesterolemia (Type II
  Hyperlipoproteinemia) Assessment by Route of
  Administration 

10
List of Tables

• Familial Hypercholesterolemia (Type II
  Hyperlipoproteinemia) Assessment by Stage and
  Route of Administration Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) Assessment by Molecule Type Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) Assessment by Stage and Molecule Type Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) Therapeutics Discontinued Products Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) Therapeutics Dormant ProductsProducts under
  Development by Companies, 2014

11
List of Figures

• Number of Products under Development for Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ), 2014Late Clinical Stage Products (Filed and
  Phase III), 2014Mid Clinical Stage Products
  (Phase II), 2014Early Clinical Stage Products
  (Phase I and IND Filed), 2014Discovery and
  Pre-Clinical Stage Products, 2014Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) Assessment by Monotherapy Products Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) Assessment by Combination Products Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) Assessment by Route of Administration Familial
  Hypercholesterolemia (Type II Hyperlipoproteinemia
  ) Assessment by Stage and Route of
  Administration Familial Hypercholesterolemia
  (Type II Hyperlipoproteinemia) Assessment by
  Molecule Type Familial Hypercholesterolemia
  (Type II Hyperlipoproteinemia) Assessment by
  Stage and Molecule Type

12
Related Reports

• The Mobile Healthcare (mHealth) Bible 2014 -
  2020
• Pregnancy Detection Kit Market in the US
  2015-2019
• Global Prenatal and Newborn Genetic Testing
  Market 2015-2019
• Global Knee Implant market 2015-2019
• Global Isosorbide Market 2015-2019

13

• Familial Hypercholesterolemia (Type II
  Hyperlipoproteinemia)-Pipeline Insights, 2014
• Published Dec. 2014 60 Pages
• DelveInsights, Familial Hypercholesterolemia
  (Type II Hyperlipoproteinemia)-Pipeline Insights,
  2014, report provides comprehensive insights
  about pipeline drugs across this indication.
  Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953

• You Can Visit http//www.aarkstore.com
• OR Mail us at contact_at_aarkstore.com
• Blog
• http//www.aarkstore.com/blog/
• Conference
• http//conference.aarkstore.com/
• News
• http//www.aarkstore.com/news